{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/nausea-vomiting-in-pregnancy/prescribing-information/metoclopramide/","result":{"pageContext":{"chapter":{"id":"130049ea-689b-545a-a2c3-05f0dd6e75a9","slug":"metoclopramide","fullItemName":"Metoclopramide","depth":2,"htmlHeader":"<!-- begin field 44e6cb43-4dd1-41ae-92c5-4311971089b7 --><h2>Metoclopramide</h2><!-- end field 44e6cb43-4dd1-41ae-92c5-4311971089b7 -->","summary":"","htmlStringContent":"<!-- begin item 7c5f79ec-34ed-449a-9602-571795668534 --><!-- end item 7c5f79ec-34ed-449a-9602-571795668534 -->","topic":{"id":"5d1ac05e-2e14-5b50-9a55-84ebd62fb88a","topicId":"866e168a-d1cc-4f14-ae38-2264dad4909d","topicName":"Nausea/vomiting in pregnancy","slug":"nausea-vomiting-in-pregnancy","lastRevised":"Last revised in November 2020","chapters":[{"id":"2ed30ea1-6303-508e-bc93-066f8ffbbba6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"81163ec6-a53e-53b1-9990-910cceb0be62","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9f99e883-ffa1-5d97-b703-d5bfbd68f8d5","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"81c02d2d-db72-591c-9cac-e581388698c4","slug":"changes","fullItemName":"Changes"},{"id":"845aae6a-8e35-57f1-b583-4763434044df","slug":"update","fullItemName":"Update"}]},{"id":"21afb631-a6c0-5829-b00a-3b33bef92b50","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"61081bb4-4afa-59ad-8401-21a133c7ac1e","slug":"goals","fullItemName":"Goals"},{"id":"5e20514d-0378-56ab-a9c4-6adb3b054200","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"5af11c90-393d-59dd-9a48-c750bc1a8a14","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"51bcef1b-8089-52c9-92cc-1fa55932d88b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef8fc985-dc5b-58a5-a2ff-ca6e9d55cfb8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f559ccd0-5b31-5044-9e75-d75ab6224e12","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2664bbce-4231-58ba-94b3-9154bbe463ce","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"474f1c82-889d-5487-9620-c2c4c6869f1b","slug":"definition","fullItemName":"Definition"},{"id":"8eb8a14e-f0bc-5bde-941f-077c2ebf80e8","slug":"causes","fullItemName":"Causes"},{"id":"6086e58d-ce8f-56ba-8bc9-6769de656e20","slug":"associated-factors","fullItemName":"Associated factors"},{"id":"843ada21-2019-53fe-96b9-02ac02e7d0f2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"87b6f2c0-0cd6-59f3-9359-e145dc966385","slug":"complications","fullItemName":"Complications"}]},{"id":"d56e419a-1cce-586b-b99b-a5b8a8990006","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1f17249a-f4a8-55a7-aac0-221f3958f18f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b917da16-f352-5806-8109-438dbc9bbf0b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"92cdc482-cd10-5234-96f9-a47cf0d7a2d1","fullItemName":"Management","slug":"management","subChapters":[{"id":"110c4bdc-fe27-5536-9a99-bfbcf04edc46","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"f416e06b-d171-5ff0-8c08-5bc1edd42843","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"130049ea-689b-545a-a2c3-05f0dd6e75a9","slug":"metoclopramide","fullItemName":"Metoclopramide"},{"id":"b1e3f566-e2f8-55a2-989a-e0a05d5ec1e2","slug":"ondansetron","fullItemName":"Ondansetron"},{"id":"5ab79693-69e2-58b9-b27b-5ccf74d1a7b5","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"715f035d-267f-5933-b2b0-7d3ee3bd6430","slug":"promethazine","fullItemName":"Promethazine"}]},{"id":"85b35812-d5b1-58c1-83b2-54c180386588","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1a1884de-e81c-54af-b11f-6b0868c50cc8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8a6cb0f6-92e2-57f4-9a1e-bf9e54371e08","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4dc13c44-10ce-581a-a0a4-039b81c0c21e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"cb1eb43f-2d9f-59be-8318-3bd84b8d0c3f","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b024ff4-e12a-55bd-ae23-668d6ca9e645","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e5cef950-067b-517f-9adb-2be42bf3be6f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dbe95893-89e8-5737-9b03-95b5280f9823","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"93dd4a9b-e268-51a6-ad4d-89d5e9f8a3ab","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1114ae8d-c264-59f8-8b49-43a131d0904d","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 368e9ea9-5958-4fff-99d7-a77400a8447f --><h3>What dosage of metoclopramide should I prescribe?</h3><!-- end field 368e9ea9-5958-4fff-99d7-a77400a8447f -->","summary":"","htmlStringContent":"<!-- begin item b35dfe75-2341-454f-9cda-a77400a841de --><!-- begin field da1ad158-0a48-4bd3-b704-a77400a8447f --><ul><li>For adults over 18 years of age weighing:<ul><li>60 kg or more, prescribe metoclopramide 10 mg orally up to three times a day (for a maximum of 5 days). </li><li>Less than 60 kg, the maximum daily dose is 500 micrograms/kg in three divided doses (for a maximum of 5 days).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">RCOG, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field da1ad158-0a48-4bd3-b704-a77400a8447f --><!-- end item b35dfe75-2341-454f-9cda-a77400a841de -->","subChapters":[]},{"id":"49a9fb29-8ae6-5785-8aad-580dbd92649a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ffc8b0db-939a-4303-a5e3-a77400a87947 --><h3>What are the adverse effects of metoclopramide?</h3><!-- end field ffc8b0db-939a-4303-a5e3-a77400a87947 -->","summary":"","htmlStringContent":"<!-- begin item d2ef1ce2-ca45-43bc-b5df-a77400a87725 --><!-- begin field ed9be43f-c3fc-4ce1-b9a3-a77400a87947 --><ul><li><strong>Neurological disorders</strong><ul><li>Metoclopramide can induce acute dystonic reactions involving facial and skeletal muscle spasms, and oculogyric crises (an acute dystonic reaction of the ocular muscles characterized by bilateral dystonic elevation of visual gaze lasting from seconds to hours). Prolonged treatment with metoclopramide may cause potentially irreversible tardive dyskinesia (uncontrollable movements such as grimacing and twitching), especially in the elderly.</li><li>These effects:<ul><li>Are more common in children and young people and/or when high doses are used.</li><li>Usually occur shortly after starting treatment with metoclopramide and can occur after a single administration.</li><li>Are generally reversible after treatment is discontinued, but symptomatic treatment may be needed following specialist advice.</li></ul></li><li>To help minimize the risk metoclopramide should be prescribed for no longer than 5 days.<ul><li>Discontinue metoclopramide immediately if the person experiences extrapyramidal symptoms.</li></ul></li></ul></li><li><strong>Cardiac disorders</strong><ul><li>There have been reports of serious cardiovascular adverse effects, including cases of severe bradycardia, cardiac arrest, and QT prolongation, following administration of metoclopramide by injection.<ul><li>Special care should be taken when administering metoclopramide to elderly people; people with cardiac conduction disturbances (including QT prolongation), uncorrected electrolyte imbalance, and bradycardia; and people taking other drugs known to prolong the QT interval.</li></ul></li></ul></li><li><strong>Effects on ability to drive and use machines</strong><ul><li>Metoclopramide may cause drowsiness, dizziness, dyskinesia (uncommon), and dystonias which may affect the person's vision and ability to drive and operate machinery.</li></ul></li><li><strong>Other adverse effects of metoclopramide include:</strong><ul><li>Common: diarrhoea, weakness, somnolence, depression, and hypotension.</li><li>Uncommon: amenorrhoea, hyperprolactinaemia, hallucinations, depressed level of consciousness, and hypersensitivity reactions.</li><li>Rare: galactorrhoea, confusion, and convulsion (especially in people with epilepsy).</li><li>Unknown frequency: gynaecomastia, anaphylactic reaction (including anaphylactic shock), shock, and neuroleptic malignant syndrome.</li></ul></li><li>If metoclopramide is taken at the end of pregnancy, there is a possibility of extrapyramidal syndrome in the newborn, therefore metoclopramide should be avoided at this time.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">Koban, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field ed9be43f-c3fc-4ce1-b9a3-a77400a87947 --><!-- end item d2ef1ce2-ca45-43bc-b5df-a77400a87725 -->","subChapters":[]},{"id":"43da9320-ebcc-5ffc-8a45-3c76a0f69216","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5dc18ce1-c257-442c-98b4-a77400a85c6c --><h3>What are the contraindications and cautions when prescribing metoclopramide?</h3><!-- end field 5dc18ce1-c257-442c-98b4-a77400a85c6c -->","summary":"","htmlStringContent":"<!-- begin item 5d18828e-be49-4ed3-860e-a77400a85a1f --><!-- begin field 1bff5387-b22a-4c28-84e0-a77400a85c6c --><ul><li><strong>Do not prescribe metoclopramide to:</strong><ul><li>People with:<ul><li>Gastrointestinal haemorrhage, obstruction, or perforation.</li><li>Confirmed or suspected phaeochromocytoma — due to the risk of severely hypertensive episodes.</li><li>History of neuroleptic or metoclopramide-induced tardive dyskinesia.</li><li>Epilepsy — increased frequency and intensity of seizures.</li><li>Parkinson's disease.</li><li>Known history of methaemoglobinaemia with metoclopramide or of NADH (nicotinamide adenine dinucleotide) cytochrome-b5 deficiency.</li></ul></li></ul></li><li><strong>Prescribe metoclopramide with caution to:</strong><ul><li>Elderly people — consider a dose reduction based on renal and hepatic function and overall frailty.</li><li>People with:<ul><li>Chronic kidney disease (CKD) — in end stage renal disease (creatinine clearance 15 mL/min or less), reduce the daily dose by 75%. In moderate to severe renal impairment (creatinine clearance 15–60 mL/min), reduce the dose by 50%.</li><li>Hepatic impairment — in people with severe hepatic impairment, reduce the total daily dose by 50%.</li><li>Cardiac conduction disturbances (including QT interval prolongation), uncorrected electrolyte imbalance, or bradycardia.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field 1bff5387-b22a-4c28-84e0-a77400a85c6c --><!-- end item 5d18828e-be49-4ed3-860e-a77400a85a1f -->","subChapters":[]},{"id":"f36a238c-3f62-5255-b18c-94765972ce55","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 9b9af2bb-1489-46e3-8113-a77400a88e41 --><h3>What drug interactions occur with metoclopramide?</h3><!-- end field 9b9af2bb-1489-46e3-8113-a77400a88e41 -->","summary":"","htmlStringContent":"<!-- begin item 435c1ab9-865e-4f1c-8967-a77400a88c2a --><!-- begin field 609d6e7b-7325-4ca5-b6a6-a77400a88e41 --><ul><li><strong>Alcohol </strong>— warn people that metoclopramide possibly increases the absorption of alcohol, and its sedative effects.<ul><li>The degree of these effects will depend on the person.</li></ul></li><li><strong>Antipsychotics </strong>— concurrent use with metoclopramide should be done cautiously.<ul><li>There have been reports of increased risk of extrapyramidal adverse effects when metoclopramide is given with an antipsychotic drug.</li></ul></li><li><strong>Antimuscarinic drugs </strong>— there is an increased risk of antimuscarinic adverse effects when metoclopramide is given with other antimuscarinic drugs. Concurrent use can also lead to confusion in the elderly.<ul><li>In addition, the gastrointestinal effects of metoclopramide are antagonized by other antimuscarinic drugs.</li></ul></li><li><strong>Atovaquone</strong> — avoid concurrent use.<ul><li>Metoclopramide reduces plasma concentration of atovaquone.</li></ul></li><li><strong>Ciclosporin </strong>— monitor ciclosporin plasma concentration carefully.<ul><li>Metoclopramide increases plasma concentration of ciclosporin.</li></ul></li><li><strong>Dopamine agonists </strong>— concurrent use is contraindicated.<ul><li>Metoclopramide opposes the effect of dopamine agonists, leading to a reduction in clinical response.</li><li>Metoclopramide is also expected to reduce the prolactin-lowering effect of bromocriptine.</li></ul></li><li><strong>Levodopa </strong>— concurrent use is contraindicated.<ul><li>Metoclopramide can oppose the effects of levodopa and worsen Parkinson's disease.</li></ul></li><li><strong>Selective serotonin reuptake inhibitors (SSRIs) </strong>— monitor the person for increased adverse effects.<ul><li>There have been case reports of serotonin syndrome in people taking an SSRI with metoclopramide.</li><li>Extrapyramidal symptoms have occurred in people given fluoxetine, fluvoxamine, or sertraline with metoclopramide.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">ABPI Medicines Compendium, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/references/\">BNF 73, 2017</a>]</p><!-- end field 609d6e7b-7325-4ca5-b6a6-a77400a88e41 --><!-- end item 435c1ab9-865e-4f1c-8967-a77400a88c2a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}